Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review May 8, 2024May 8, 2024
New data independently confirms and extends laboratory findings and expands safety profile of ATH434 August 4, 2020August 16, 2022
